Oral News and Research

RSS

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

The World Health Organization released its 2015 updated essential medicines list and for the first time included the progesterone contraceptive vaginal ring (CVR), a contraceptive safe and effective for lactating women in the postpartum period.

10 Jun 2015

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps that include the consistent use of experienced medical teams for a single type of surgery, preemptive antibiotics before the procedure, less reliance on potent opioids during recovery and urging patients to get out of bed and move around sooner can not only prevent infections, blood clots and other serious complications in people undergoing colorectal operations, but can also accelerate recovery and reduce cost of care, according to results of an ongoing program at The Johns Hopkins Hospital.

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

Enhancing body's gut defense system can reverse bloodstream infections

An upset in the body's natural balance of gut bacteria that may lead to life-threatening bloodstream infections can be reversed by enhancing a specific immune defense response, UT Southwestern Medical Center researchers have found.

9 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

People now have powerful new option for relieving dry mouth symptoms

People who suffer from dry mouth, or xerostomia, now have a powerful new option for relieving their symptoms. Building on the success of its antioxidant oral care product line, Dallas-based PerioSciences LLC is launching Dry Mouth AO ProGel and a new MILD formula of its Hydrating AO ProRinse. The new products, along with the established Hydrating AO ProRinse and AO ProToothpaste, provide a complete Hydrating Oral Care System.

8 Jun 2015

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Patients undergoing colon and rectal operations who participated in an innovative quality improvement (QI) program to speed their recovery and enhance results experienced shorter hospitalizations, reduced infection rates, and lower hospital costs, according to new study results.

8 Jun 2015

Young children who receive surgical anesthesia have diminished brain function

Children who received general anesthesia for surgery before age 4 had diminished language comprehension, lower IQ and decreased gray matter density in posterior regions of their brain, according to a new study in the journal Pediatrics.

8 Jun 2015

Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care

New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed (‘add-on’), is linked to future patient self-care and well-being.1 Data from the IntroDia™ Survey have quantitatively demonstrated this link in the largest international survey of its kind, using responses from 4,235 people with T2D across 26 countries.

7 Jun 2015

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's tentative approval last week of lopinavir/ritonavir (LPV/r) oral pellets developed by the Indian generic company Cipla.

5 Jun 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Jun 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

4 Jun 2015

Investigators patent novel technique for detecting carcinomas in oral mucosa

Malignant tumours of the oral cavity are the sixth leading cause of cancer-related deaths worldwide. As such, a fast and accurate diagnosis is key to maximising the probability of successful treatment and the hope and quality of life of patients.

4 Jun 2015

Portable microendoscope could eliminate need for costly biopsies for esophageal cancer patients

In a clinical study of patients in the United States and China, researchers found that a low-cost, portable, battery-powered microendoscope developed by Rice University bioengineers could eventually eliminate the need for costly biopsies for many patients undergoing standard endoscopic screening for esophageal cancer.

3 Jun 2015

Toothbrushes can serve as vector for transmission of fecal coliforms in communal bathrooms

Data confirms that there is transmission of fecal coliforms in communal bathrooms at Quinnipiac University and that toothbrushes can serve as a vector for transmission of potentially pathogenic organisms. This research is presented at the annual meeting of the American Society for Microbiology.

3 Jun 2015

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex Therapeutics, Inc. today presented positive results from the Company’s randomized, double‐blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII‐positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology in Chicago.

2 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

Oral News and Research

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Lycera forms exclusive global collaboration with Celgene

Enhancing body's gut defense system can reverse bloodstream infections

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

People now have powerful new option for relieving dry mouth symptoms

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Young children who receive surgical anesthesia have diminished brain function

Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Investigators patent novel technique for detecting carcinomas in oral mucosa

Portable microendoscope could eliminate need for costly biopsies for esophageal cancer patients

Toothbrushes can serve as vector for transmission of fecal coliforms in communal bathrooms

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News